Zacks: Aptevo Therapeutics Inc (APVO) Given Consensus Rating of “Strong Buy” by Brokerages
Shares of Aptevo Therapeutics Inc (NASDAQ:APVO) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus target price of $6.00 for the company and are anticipating that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aptevo Therapeutics an industry rank of 191 out of 265 based on the ratings given to its competitors.
Separately, ValuEngine lowered Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 10th.
Aptevo Therapeutics (APVO) opened at $3.19 on Friday. The company has a current ratio of 7.76, a quick ratio of 7.67 and a debt-to-equity ratio of 0.19. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.85.
TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/03/03/zacks-aptevo-therapeutics-inc-apvo-given-consensus-rating-of-strong-buy-by-brokerages.html.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.